ADC Therapeutics SA (ADCT)

1.14USD +1.79% (+0.02)

Over 1M: +8.6%

Style
Area Line Line with markers Steps Candles Hollow candles Bars

Candles and bars need the day’s open, high and low, and need room to be drawn in: past about a year of trading a body is thinner than a hairline, so those three offer the longest window that fits instead.

1 1.1 1.2
31 Jul 5 Aug 10 Aug 13 Aug 18 Aug 21 Aug 26 Aug

Financials Quarterly

Figures
Revenue Gross Profit Operating Income Cost of Revenue Operating Cash Flow Free Cash Flow Net Income

A share count and earnings a share are not here: neither is money, so neither can share this axis. Both have their own panel on All charts.

All charts ›
Q3 '21 — Net Income: -71.5M Q4 '21 — Net Income: -34.4M Q1 '22 — Net Income: -16.7M Q2 '22 — Net Income: -64.4M Q3 '22 — Net Income: -50.6M Q4 '22 — Net Income: -24.2M Q1 '23 — Net Income: -59.4M Q2 '23 — Net Income: -48.9M Q3 '23 — Net Income: -46.7M Q4 '23 — Net Income: -85M Q1 '24 — Net Income: -46.6M Q2 '24 — Net Income: -36.5M Q3 '24 — Net Income: -44M Q4 '24 — Net Income: -30.7M Q1 '25 — Net Income: -38.6M Q2 '25 — Net Income: -56.6M Q3 '25 — Net Income: -41M Q4 '25 — Net Income: -6.4M Q1 '26 — Net Income: -33M Q2 '26 — Net Income: -16.6M -80M -60M -40M -20M 0
Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26
Net Income

Figures as at 2026-06-30, reported in USD. The newest fact in the filings is dated 2026-06-30, 62 days ago. Nothing on this page is advice.

How it scores

Five questions, each answered by the measures under it. Every figure is the company's own; the bar beside it is where that figure sits among the companies read here — the top fifth, the bottom fifth, or somewhere between. Not among all listed companies, and for a valuation multiple the low end is the good end.

Quality

How much of the revenue is really kept — and what did it take to earn it?

1.9
SBC / sales 12.1%
OE margin -140.7%
Oper. margin -125.1%
Accruals 1.9%
EBITDA margin -124.2%
FCF margin -128.5%
OCF margin -128.5%
Profit margin -121.8%
ROA -34.7%
ROCE -51.6%
Gross margin —
OCF / EBIT —
ROE —
ROIC —

4 of 17 counted in the score. The rest are measures this model does not include here, or figures these filings do not carry — switch any of them on and the score changes.

Valuation

What does the price ask for what the company earns, owns and pays out?

4.8
EV/OE 0.59×
EV/Sales -0.83×
P/C 0.67×
FCF yield -69.7%
Div. yield —
EV/EBIT —
EV/GP —
Fwd P/E —
P/B —
P/E —
PEG —

2 of 12 counted in the score. The rest are measures this model does not include here, or figures these filings do not carry — switch any of them on and the score changes.

Durability

How predictable is the revenue, and how much of it is already committed?

2.3
RPO / sales —
RPO growth —
Segment HHI —

3 of 7 counted in the score. The rest are measures this model does not include here, or figures these filings do not carry — switch any of them on and the score changes.

Resilience

Can the balance sheet absorb a bad year?

6.5
ND/EBITDA -3.2
Cash / Debt 35.5×
Debt payback 0.0 yr
Quick ratio 3.0×
Cash runway 2.1 yr
F-score 5.6 pts
Debt / Eq —
Equity / Assets —
Payout —

3 of 12 counted in the score. The rest are measures this model does not include here, or figures these filings do not carry — switch any of them on and the score changes.

Growth

Is the business getting bigger, and is it getting more profitable?

3.6
Sales CAGR 4Y +24.4%
Sales/sh Y/Y -21.2%
Sales Q/Q +2.2%
Shares change +30.8%
Div. growth —
EBIT CAGR —
EBIT Y/Y —
EPS CAGR 4Y —
EPS Y/Y —
EPS next Y —

4 of 13 counted in the score. The rest are measures this model does not include here, or figures these filings do not carry — switch any of them on and the score changes.

A measure absent from a block could not be computed from this company's filings. It is left out rather than scored as though it were bad, and the dimension is averaged over what remains. A score is measured against a fixed scale this model states; the bar is measured against the other companies, so the two can disagree — and where they do, that disagreement is the more interesting figure.